UroGen Pharma Ltd. Share-based Payment Arrangement, Expense
UroGen Pharma Ltd. (URGN) reported Share-based Payment Arrangement, Expense of $5.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- UroGen Pharma Ltd. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $5.33M, a 95.06% increase year-over-year.
- UroGen Pharma Ltd. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $4.63M, a 50.77% increase year-over-year.
- UroGen Pharma Ltd. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $3.13M, a 5.24% decline year-over-year.
- UroGen Pharma Ltd. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $3.03M, a 13.24% decline year-over-year.
- UroGen Pharma Ltd. share-based payment arrangement, expense for fiscal 2025 was $11.96M, a 8.77% decline from fiscal 2024.
- UroGen Pharma Ltd. share-based payment arrangement, expense for fiscal 2024 was $13.11M, a 40.28% increase from fiscal 2023.
- UroGen Pharma Ltd. share-based payment arrangement, expense for fiscal 2023 was $9.34M, a 11.68% decline from fiscal 2022.
- UroGen Pharma Ltd. share-based payment arrangement, expense for fiscal 2022 was $10.58M, a 54.22% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $5.33M 10-Q · filed 2026-08-05 | $9.96M 10-Q · filed 2026-08-05 | $13.09M derived: sum of 3 quarters · filed 2026-08-05 | $16.11M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $4.63M 10-Q · filed 2026-05-06 | $7.76M derived: sum of 2 quarters · filed 2026-05-06 | $10.78M derived: sum of 3 quarters · filed 2026-05-06 | $13.52M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.16M derived: sum of 2 quarters · filed 2026-03-02 | $8.89M derived: sum of 3 quarters · filed 2026-08-05 | $11.96M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $3.03M 10-Q · filed 2025-11-06 | $5.76M derived: sum of 2 quarters · filed 2026-08-05 | $8.83M 10-Q · filed 2025-11-06 | $12.13M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.73M 10-Q · filed 2026-08-05 | $5.80M 10-Q · filed 2026-08-05 | $9.11M derived: sum of 3 quarters · filed 2026-08-05 | $12.59M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $3.07M 10-Q · filed 2026-05-06 | $6.37M derived: sum of 2 quarters · filed 2026-05-06 | $9.86M derived: sum of 3 quarters · filed 2026-05-06 | $13.42M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.79M derived: sum of 2 quarters · filed 2026-03-02 | $10.35M derived: sum of 3 quarters · filed 2026-03-02 | $13.11M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $3.49M 10-Q · filed 2025-11-06 | $7.05M derived: sum of 2 quarters · filed 2025-11-06 | $9.80M 10-Q · filed 2025-11-06 | $12.42M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $3.56M 10-Q · filed 2025-08-07 | $6.32M 10-Q · filed 2025-08-07 | $8.93M derived: sum of 3 quarters · filed 2025-08-07 | $11.15M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $2.76M 10-Q · filed 2025-05-12 | $5.37M derived: sum of 2 quarters · filed 2025-05-12 | $7.59M derived: sum of 3 quarters · filed 2025-05-12 | $9.81M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $4.84M derived: sum of 2 quarters · filed 2025-03-10 | $7.06M derived: sum of 3 quarters · filed 2025-03-10 | $9.34M 10-K · filed 2025-03-10 | $9.34M 10-K · filed 2024-03-14 |
| 2023-09-30 | $2.22M 10-Q · filed 2024-11-06 | $4.45M derived: sum of 2 quarters · filed 2024-11-06 | $6.73M 10-Q · filed 2024-11-06 | $9.10M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $2.22M 10-Q · filed 2024-08-13 | $4.51M 10-Q · filed 2024-08-13 | $6.88M derived: sum of 3 quarters · filed 2024-08-13 | $9.32M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $2.29M 10-Q · filed 2024-05-13 | $4.65M derived: sum of 2 quarters · filed 2024-05-13 | $7.09M derived: sum of 3 quarters · filed 2024-05-13 | $9.92M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $4.81M derived: sum of 2 quarters · filed 2024-03-14 | $7.63M derived: sum of 3 quarters · filed 2024-03-14 | $10.58M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $2.44M 10-Q · filed 2023-11-14 | $5.26M derived: sum of 2 quarters · filed 2023-11-14 | $8.21M 10-Q · filed 2023-11-14 | $13.57M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $2.82M 10-Q · filed 2023-08-10 | $5.77M 10-Q · filed 2023-08-10 | $11.13M derived: sum of 3 quarters · filed 2023-08-10 | $16.64M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $2.95M 10-Q · filed 2023-05-11 | $8.31M derived: sum of 2 quarters · filed 2023-05-11 | $13.82M derived: sum of 3 quarters · filed 2023-05-11 | $19.87M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $10.87M derived: sum of 2 quarters · filed 2023-03-24 | $16.92M derived: sum of 3 quarters · filed 2023-03-24 | $23.11M 10-K · filed 2023-03-24 | |
| 2021-09-30 | $5.51M 10-Q · filed 2022-11-10 | $11.56M derived: sum of 2 quarters · filed 2022-11-10 | $17.76M 10-Q · filed 2022-11-10 | $24.28M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $6.05M 10-Q · filed 2022-08-11 | $12.24M 10-Q · filed 2022-08-11 | $18.77M derived: sum of 3 quarters · filed 2022-08-11 | $25.53M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $6.20M 10-Q · filed 2022-05-10 | $12.72M derived: sum of 2 quarters · filed 2022-05-10 | $19.48M derived: sum of 3 quarters · filed 2022-05-10 | $26.60M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $6.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $13.29M derived: sum of 2 quarters · filed 2022-03-21 | $20.41M derived: sum of 3 quarters · filed 2022-03-21 | $28.02M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $6.76M 10-Q · filed 2021-11-15 | $13.88M derived: sum of 2 quarters · filed 2021-11-15 | $21.50M 10-Q · filed 2021-11-15 | $29.56M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $7.12M 10-Q · filed 2021-08-04 | $14.74M 10-Q · filed 2021-08-04 | $22.80M derived: sum of 3 quarters · filed 2021-08-04 | $30.04M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | $7.62M 10-Q · filed 2021-05-13 | $15.68M derived: sum of 2 quarters · filed 2021-05-13 | $22.93M derived: sum of 3 quarters · filed 2021-05-13 | $30.14M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $8.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $15.31M derived: sum of 2 quarters · filed 2021-03-18 | $22.52M derived: sum of 3 quarters · filed 2021-03-18 | $29.97M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $7.24M 10-Q · filed 2020-11-09 | $14.46M derived: sum of 2 quarters · filed 2020-11-09 | $21.90M 10-Q · filed 2020-11-09 | $30.78M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $7.21M 10-Q · filed 2020-08-10 | $14.66M 10-Q · filed 2020-08-10 | $23.54M derived: sum of 3 quarters · filed 2020-08-10 | $33.05M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $7.45M 10-Q · filed 2020-05-07 | $16.32M derived: sum of 2 quarters · filed 2020-05-07 | $25.84M derived: sum of 3 quarters · filed 2020-05-07 | $33.55M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $18.39M derived: sum of 2 quarters · filed 2020-03-02 | $26.10M derived: sum of 3 quarters · filed 2020-03-02 | $30.64M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $9.52M 10-Q · filed 2019-11-12 | $17.22M derived: sum of 2 quarters · filed 2019-11-12 | $21.77M 10-Q · filed 2019-11-12 | $24.03M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $7.71M 10-Q · filed 2019-08-09 | $12.25M 10-Q · filed 2019-08-09 | $14.52M derived: sum of 3 quarters · filed 2020-03-02 | $16.68M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $4.54M 10-Q · filed 2019-05-09 | $6.81M derived: sum of 2 quarters · filed 2020-03-02 | $8.97M derived: sum of 3 quarters · filed 2020-03-02 | $10.54M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | $2.27M derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $4.43M derived: sum of 2 quarters · filed 2020-03-02 | $6.00M derived: sum of 3 quarters · filed 2020-03-02 | $6.30M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $2.16M 6-K · filed 2018-11-13 | $3.73M derived: sum of 2 quarters · filed 2018-11-13 | $4.03M 6-K · filed 2018-11-13 | ||
| 2017-06-30 | $1.58M 6-K · filed 2018-08-14 | $1.87M 6-K · filed 2018-08-14 | |||
| 2017-03-31 | $297.00K 6-K · filed 2018-05-15 | ||||
| 2016-12-31 | $1.97M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $449.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |